Vinblastine treatment of Hodgkin's disease. Selected observations of vinca alkaloid dose schedules in man and animals

Raymond Lenhard, A. H. Owens, R. J. Owellen

Research output: Contribution to journalArticle

Abstract

Vinblastine, 0.3 mg/kg, was given every 2 wk for 4 mth to 8 patients with Stages IIIB and IV Hodgkin's disease who had received no prior therapy. There was a complete remission in 3 patients and a partial remission in 2. Moderate bone marrow toxicity (no white blood cell count less than 1000) occurred in 3 patients. Marked neurotoxicity was seen in all 5 patients who obtained a tumor response, but not in those whose Hodgkin's disease failed to respond. In addition, several patients who experienced marked neurotoxicity following vinblastine were able later to receive the usually more neurotoxic drug, vincristine, without developing neuropathy. Other modifications in dose and schedule of the vinca alkaloids may minimize toxicity and provide for improved therapeutic ratio.

Original languageEnglish (US)
Pages (from-to)211-217
Number of pages7
JournalJohns Hopkins Medical Journal
Volume134
Issue number4
StatePublished - Dec 1 1974

Fingerprint

Vinca Alkaloids
Vinblastine
Hodgkin Disease
Appointments and Schedules
Therapeutics
Vincristine
Leukocyte Count
Bone Marrow
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vinblastine treatment of Hodgkin's disease. Selected observations of vinca alkaloid dose schedules in man and animals. / Lenhard, Raymond; Owens, A. H.; Owellen, R. J.

In: Johns Hopkins Medical Journal, Vol. 134, No. 4, 01.12.1974, p. 211-217.

Research output: Contribution to journalArticle

@article{43a05f42e951435786fec5ac21348f3b,
title = "Vinblastine treatment of Hodgkin's disease. Selected observations of vinca alkaloid dose schedules in man and animals",
abstract = "Vinblastine, 0.3 mg/kg, was given every 2 wk for 4 mth to 8 patients with Stages IIIB and IV Hodgkin's disease who had received no prior therapy. There was a complete remission in 3 patients and a partial remission in 2. Moderate bone marrow toxicity (no white blood cell count less than 1000) occurred in 3 patients. Marked neurotoxicity was seen in all 5 patients who obtained a tumor response, but not in those whose Hodgkin's disease failed to respond. In addition, several patients who experienced marked neurotoxicity following vinblastine were able later to receive the usually more neurotoxic drug, vincristine, without developing neuropathy. Other modifications in dose and schedule of the vinca alkaloids may minimize toxicity and provide for improved therapeutic ratio.",
author = "Raymond Lenhard and Owens, {A. H.} and Owellen, {R. J.}",
year = "1974",
month = "12",
day = "1",
language = "English (US)",
volume = "134",
pages = "211--217",
journal = "Johns Hopkins Medical Journal",
issn = "0021-7263",
publisher = "Johns Hopkins University Press",
number = "4",

}

TY - JOUR

T1 - Vinblastine treatment of Hodgkin's disease. Selected observations of vinca alkaloid dose schedules in man and animals

AU - Lenhard, Raymond

AU - Owens, A. H.

AU - Owellen, R. J.

PY - 1974/12/1

Y1 - 1974/12/1

N2 - Vinblastine, 0.3 mg/kg, was given every 2 wk for 4 mth to 8 patients with Stages IIIB and IV Hodgkin's disease who had received no prior therapy. There was a complete remission in 3 patients and a partial remission in 2. Moderate bone marrow toxicity (no white blood cell count less than 1000) occurred in 3 patients. Marked neurotoxicity was seen in all 5 patients who obtained a tumor response, but not in those whose Hodgkin's disease failed to respond. In addition, several patients who experienced marked neurotoxicity following vinblastine were able later to receive the usually more neurotoxic drug, vincristine, without developing neuropathy. Other modifications in dose and schedule of the vinca alkaloids may minimize toxicity and provide for improved therapeutic ratio.

AB - Vinblastine, 0.3 mg/kg, was given every 2 wk for 4 mth to 8 patients with Stages IIIB and IV Hodgkin's disease who had received no prior therapy. There was a complete remission in 3 patients and a partial remission in 2. Moderate bone marrow toxicity (no white blood cell count less than 1000) occurred in 3 patients. Marked neurotoxicity was seen in all 5 patients who obtained a tumor response, but not in those whose Hodgkin's disease failed to respond. In addition, several patients who experienced marked neurotoxicity following vinblastine were able later to receive the usually more neurotoxic drug, vincristine, without developing neuropathy. Other modifications in dose and schedule of the vinca alkaloids may minimize toxicity and provide for improved therapeutic ratio.

UR - http://www.scopus.com/inward/record.url?scp=0016380427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016380427&partnerID=8YFLogxK

M3 - Article

C2 - 4821134

AN - SCOPUS:0016380427

VL - 134

SP - 211

EP - 217

JO - Johns Hopkins Medical Journal

JF - Johns Hopkins Medical Journal

SN - 0021-7263

IS - 4

ER -